CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

125388Orig1s000

SUMMARY REVIEW
## Summary Review for Regulatory Action

<table>
<thead>
<tr>
<th>Date</th>
<th>(electronic stamp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>From</td>
<td>Ann. T. Farrell, M.D., Acting Division Director</td>
</tr>
<tr>
<td>Subject</td>
<td>Division Director Summary Review</td>
</tr>
<tr>
<td>NDA/BLA #</td>
<td>125388</td>
</tr>
<tr>
<td>Supplement #</td>
<td></td>
</tr>
<tr>
<td>Applicant Name</td>
<td>Seattle Genetics, Inc.</td>
</tr>
<tr>
<td>Date of Submission</td>
<td>February 28, 2011</td>
</tr>
<tr>
<td>PDUFA Goal Date</td>
<td>August 30, 2011</td>
</tr>
<tr>
<td>Proprietary Name /</td>
<td>Adcetris/brentuximab vedotin</td>
</tr>
<tr>
<td>Established (USAN) Name</td>
<td></td>
</tr>
<tr>
<td>Dosage Forms / Strength</td>
<td>Intravenous infusion administered at 1.8 mg/kg every 21 days/ 50 mg single use vial</td>
</tr>
<tr>
<td>Proposed Indication(s)</td>
<td>Treatment of Relapsed or Refractory Hodgkin Lymphoma</td>
</tr>
<tr>
<td>Action/Recommended Action for NME:</td>
<td>Accelerated Approval</td>
</tr>
</tbody>
</table>

### Material Reviewed/Consulted

<table>
<thead>
<tr>
<th>OND Action Package, including:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Officer Review</td>
</tr>
<tr>
<td>Statistical Review</td>
</tr>
<tr>
<td>Pharmacology Toxicology Review</td>
</tr>
<tr>
<td>CMC Review/OBP and ONDQA</td>
</tr>
<tr>
<td>Reviews and Micro review</td>
</tr>
<tr>
<td>Microbiology Review</td>
</tr>
<tr>
<td>Clinical Pharmacology Review</td>
</tr>
<tr>
<td>DDMAC</td>
</tr>
<tr>
<td>DSI</td>
</tr>
<tr>
<td>CDTL Review</td>
</tr>
<tr>
<td>OSE/DMEPA</td>
</tr>
<tr>
<td>OSE/DDRE</td>
</tr>
<tr>
<td>OSE/DSRCS</td>
</tr>
<tr>
<td>Other –MHT</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>IRT</td>
</tr>
</tbody>
</table>
Signatory Authority Review Template

1. Introduction

On February 28, 2011, Seattle Genetics submitted BLA 125399 proposed for the treatment of patients with relapsed or refractory Hodgkin Lymphoma (HL).

Brentuximab vedotin is a drug-antibody conjugate [(cAC10) conjugated to SGD-1006 via thioether bonds] directed against CD30. Brentuximab vedotin has 3 components: a chimeric IgG1 antibody cAC10 specific for human CD30, an antimitotic auristatin E (MMAE), and a protease-cleavable linker that is covalently attached MMAE to cAC10. Binding of the ADC to CD30 on the cell surface initiates internalization of the ADC-CD30 complex. Within the cell, MMAE is released via proteolytic cleavage. Binding of MMAE to tubulin disrupts the microtubule network within the cell, induces cell cycle arrest, and results in apoptotic death of the CD30-expressing tumor cell.

2. Background

Hodgkin lymphoma is a hematologic malignancy characterized by the presence of Reed-Sternberg cells. Symptoms include painless enlargement of lymph nodes, spleen or other immune tissue. Other symptoms include fever, weight loss, fatigue, and night sweats.

The majority of patients who receive adequate first-line therapy (radiation or chemotherapy or a combination) are cured of their disease. However those patients with Hodgkin lymphoma who relapse or do not respond to first-line therapy will require additional therapy consisting of high-dose chemotherapy and autologous stem cell transplant (ASCT). Up to 40% of patients receiving autologous stem cell transplant eventually relapse with a historical median survival is 2 years from time of relapse post-ASCT.

3. CMC/Device

There were no issues identified that preclude approval. However there are recommended post-marketing commitments as described below.

From the CMC review:
Brentuximab vedotin (SGN-35) consists of cAC10 conjugated to SGD-1006 via thioether bonds. Each antibody molecule may have 0, 2, 4, 6, or 8 conjugated SGD-1006 molecules. On average, the drug (SGD-1006 intermediate-1006) and antibody (cAC10) molar ratio is four. Brentuximab vedotin is a heterogeneous mixture, with respect to drug conjugation ratio and also with respect to the variety of post-
translational modifications of the antibody. Hence, the calculated molecular formula and predicted average molar mass of brentuximab vedotin are based on the average molar mass of cAC10 and assume an average of four drug-linkers conjugated per antibody.

Prior to conjugation to form antibody drug conjugate, two intermediates, cAC10 and SGD-1006, are manufactured by two different contract manufacturers. cAC10 antibody is manufactured by [REDACTED]. Evaluation of the CMC information for cAC10 antibody is conducted by Dr. Marjorie Shapiro in the Office of Biotechnology Products, which is the lead office for CMC review of this BLA. SGD-1006 intermediate is manufactured by the [REDACTED]. This review evaluates the CMC information for SGD-1006 intermediate, relevant drug related information for SGN-35 bulk drug substance.

SGD-1006 intermediate
CMC information for SGD-1006 intermediate is submitted both in the BLAs and the referenced DMF [REDACTED]. Most of the SGD-1006 intermediate CMC information provided in the BLA and the DMF are the same. Review of SGD-1006 intermediate is conducted in the BLA review when the same information is submitted in both BLA and DMF. DMF [REDACTED] is reviewed for the CMC information that is only submitted in the DMF but not BLA. DMF review concludes that it is only adequate to support this BLA. Refer to the review for the DMF dated July 21, 2011.

SGD-1006 is manufactured at a commercial scale of [REDACTED]. The process consists of [REDACTED]. During drug development three manufacturing processes were used to produce SGD-1006 intermediate, Process A, B and C. [REDACTED]. Process C is the proposed commercial process. Comparability between Process A, B and C was assessed based on the results of in-process control tests, the test results from the stage intermediates, and the final intermediate SGD-1006, and the results demonstrated the lots produced by the three processes are comparable.

Specifications for SGD-1006 intermediate are proposed based on historical batch data, analytical method capability, and results of process characterization studies. Although the acceptance limits for the specified impurities levels are higher than the ICH Q3A recommended qualification thresholds, their levels at bulk drug substance are well below the ICH limit after the conjugation and purification process. Pharm/tox input for the qualification of impurities was sought, and is found to be acceptable. Method validation studies and the results are provided in the DMF.

SGD-1006 intermediate is packaged in [REDACTED].
The proposed retest date for SGD-1006 intermediate stored at is acceptable.

SGN-35 Drug Substance
SGN-35 bulk drug substance is manufactured at scale by a contract manufacturer, manufacturing starts with

Structural characterization of SGN-35 has been conducted using a comprehensive set of methods. The data confirm that SGN-35 conjugation site is at the cysteine residues resulted in many active forms with up to eight possible conjugation sites per antibody. Drug load distribution studies were conducted using HIC and RP-HPLC methods. The amount of various isoforms of drug antibody conjugates have been measured. And the relative abundance of the conjugation isoforms with respect to the average drug average drug load MR_D have been determined. Historical data for drug loading distribution and average drug load MR_D showed certain correlation.

Through process characterization studies, Seattle Genetics identified the critical step (cAC10) and CPP ( ) that affect the CQAs. Studies have demonstrated that variation or results in the change of average drug load MR_D, % unconjugated cAC10, and drug loading distribution. The AOR and NOR for have been identified. By controlling within the NOR, the SGN-35 bulk drug substance produced should have average drug load MR_D and % unconjugated cAC10 well within the proposed specification limits. Whether testing for drug load distribution should be included as part of the release testing has been evaluated. Considering the observed correlation between average drug load MR_D and drug loading distribution as well as the process understanding and process controls, testing for average drug load MR_D without drug load distribution appears to be adequate. A post-marketing commitment to reassess the acceptance limits for the bulk drug substance and drug product specifications for average drug load MR_D and % unconjugated cAC10 and further tighten the currently proposed limits is recommended, and was agreed to (7/26/2011) by Seattle Genetics. The target completion date for the fulfillment of the PMC may be coordinated with the related PMCs recommended by the Office of Biotechnology Products as needed.
SGN-35 Drug Product

ADCETRIS (brentuximab vedotin) for Injection single-use vial containing 50 mg of brentuximab vedotin as a white to off-white lyophilized cake or powder. Prior to administration, SGN-35 drug product is reconstituted with 10.5 mL of sterile Water for Injection, USP resulting in a clear to slightly opalescent, colorless solution containing 5 mg/mL SGN-35, sodium citrate, trehalose, 0.2 mg/mL polysorbate 80, pH 6.6. For administration, the reconstituted solution is added to an intravenous infusion bag containing sterile 0.9% Sodium Chloride Injection, USP.

From the CMC review, the following are post-marketing recommendations:

1. Reassess the acceptance limits for the bulk drug substance and drug product specifications for average drug load MRD and % unconjugated cAC10 and further tighten the currently proposed limits. (Note: The target completion date for the fulfillment of the PMC may be coordinated with the related PMCs recommended by the Office of Biotechnology Products, as necessary).

2. Harmonize the CMC information contained in DMF and this BLA within three months post approval. (the Applicant committed to this timing in the 7/26/2011 teleconference).

From the Product review memo:

I recommend approval of BLA 125388 and BLA 125399, for brentuximab vedotin for the treatment of patients with relapsed or refractory CD30+ post-autologous stem cell transplant for HL and ALCL.

I recommend an expiration dating period of 30 months for brentuximab vedotin drug product when stored at 2-8°C.

I recommend an expiration dating period of for brentuximab vedotin drug substance when stored at.

I recommend an expiration dating period of for cAC10 Intermediate when stored at.

The stability protocols are acceptable and the expiration dating periods for brentuximab vedotin drug product and drug substance and the cAC10 Intermediate may be extended by reporting data to the BLA Annual Report.

I recommend approval of the proposed release specifications for brentuximab vedotin drug product, brentuximab vedotin drug substance and cAC10 Intermediate. Seattle Genetics will reassess release specifications as part of the Annual Product Review and when ≥25 lots of cAC10 Intermediate and ≥10 lots of SGD-1006 have been used to manufacture drug substance.

The CMC and Product review teams recommended that this application be approved. I concur.
4. Nonclinical Pharmacology/Toxicology

There are no issues that would preclude approval.

The following text is from the Executive Summary of the Pharmacology/Toxicology review:

*Pharmacology and toxicology studies with brentuximab vedotin and/or MMAE were conducted according to ICHS9 and are considered adequate. Toxicities such as hematotoxicity, genotoxicity, and reproductive and developmental toxicities are consistent with those observed with microtubule disrupting cytotoxic agents.*

*There are no pharmacology/toxicology issues at this time that will preclude the approval of brentuximab vedotin for the proposed indications. An approval for this BLA is recommended from the pharmacology/toxicology perspective.*

I concur.

5. Clinical Pharmacology/Biopharmaceutics

There are no issues that would preclude approval. The Clinical Pharmacology and Biopharmaceuticals team recommended approval. They do not have any post-marketing commitments.

The following text is from their review:

*Brentuximab vedotin exhibited linear PK from 1.2 to 2.7 mg/kg. The half-life ranged from 4 to 6 days with minimal accumulation; steady-state was achieved in 21 days.*

I concur.

6. Microbiology

The Microbiology team has not identified issues that would preclude approval of the BLA.

7. Clinical/Statistical-Efficacy

The main trial for consideration is SG0-35-003 a phase two single arm trial. This trial is supported by phase 1 data and an second phase 2 single arm study in a related disease (systemic anaplastic large cell lymphoma).

From Dr. De Claro’s review:

*The recommendation for accelerated approval is based on the single, Phase 2, single arm, clinical trial SG035-0003 in which brentuximab vedotin showed a 32% complete remission rate with a median duration of response of 20.5 months.*
SG035-0003 enrolled 102 patients with Hodgkin lymphoma who relapsed after autologous stem cell transplant. The historical median overall survival for these patients is approximately 2 years from time of relapse post-transplant.

The trial population in SG035-0003 was mostly young adults. The mean age was 34 years. Seventy-five percent of the patients were between the ages of 18 to 39. The median number of prior lines of systemic chemotherapy was 5. Nearly all of the patients had received drugs or drug classes approved for the treatment of Hodgkin lymphoma.

This reviewer recommends that the complete remission rate and prolonged duration of remission in patients achieving CR, be used as regulatory efficacy endpoint for approval. Although the overall response rate was 73% (N=74) with a median duration of response of 6.7 months, this included 40 patients with a best response of partial remission with a median duration of response of 3.5 months.

The complete remission rate of 32% with a median duration of 20.5 months can be considered as a “clinical endpoint other than survival or irreversible morbidity” as per 21 CFR 601.41 (Accelerated Approval regulations).

The main safety issues identified by the applicant include peripheral neuropathy, myelosuppression, and infusion reactions. These risks are acceptable for a population with a life-threatening illness for which there is limited available therapy, wherein the agent is showing a high level of activity.

The efficacy and safety evaluation are limited by the small size (N=102) and the single arm design. Time-to-event endpoints such as progression free survival and overall survival cannot be adequately interpreted in a single arm trial. Patient reported outcomes were non-evaluable due to lack of a validated instrument, and the open-label nature of a single arm trial. For safety, attribution of adverse events is not possible in the absence of a control arm. Finally, initial applications, such as this application, cannot rely upon prior experience for both efficacy and safety.

I have read the statistical reviews for this application and the CDTL memo and concur with the recommendations for accelerated approval.

8. Safety

The major safety issues identified during this review are: neuropathy, neutropenia, and infusion reactions.

From the primary clinical review:
• The major safety issues identified by the applicant include peripheral neuropathy, neutropenia, infusion reactions, and one case of Stevens-Johnson syndrome.

• Peripheral neuropathy was the most common adverse event leading to treatment discontinuations (12 patients) and dose reductions (10 patients). Fifty-six patients (55%) developed treatment-emergent peripheral neuropathy. Forty patients had sensory only, 4 had motor only, and 12 had both. The median time to onset was 12.4 weeks. The risk of peripheral neuropathy increased with greater length of exposure to brentuximab. At long-term follow-up (median of 35 weeks from end of treatment), 26 of 56 patients (46%) had residual neuropathy.

• Fifty-five patients (54%) experienced any grade of neutropenia, with 21 patients (21%) experiencing Grade 3 or 4 neutropenia. Neutropenia was evaluated using the adverse event and laboratory datasets because Grade 1-2 neutropenia events were underreported to the adverse event dataset. Twenty three patients (23%) received G-CSF products during the clinical trial. One patient had neutropenic septic shock. Sixteen patients had dose delays due to neutropenia.

• Infusion reactions occurred in 14 patients (14%), all grade 1 or 2 in severity.

• One patient developed Stevens-Johnson syndrome leading to treatment discontinuation of brentuximab. However, this case was confounded by recent history of naproxen use.

• Adverse events of undetermined significance to the study population include hyperglycemia, gastrointestinal hemorrhage, pneumonitis, and pulmonary embolism. Hyperglycemia was reported as an SAE in 6 patients. One patient developed Grade 4 diabetic coma. Two patients each had SAEs of gastrointestinal hemorrhage, pneumonitis, and pulmonary embolism.

• The safety evaluation for this initial application is limited by the small study size (n=102) and the single arm design. Attribution of adverse events is not possible in a single arm design. In addition, initial applications cannot rely upon prior experience for safety.

Because a high percentage of patients are reported to have unresolved residual neuropathy, further follow-up of this adverse event is recommended to determine whether the neuropathy is permanent or resolves very gradually.

Based on the submitted data (CMC/Product, Pharmacology, Clinical Pharmacology, Clinical and Statistical) and the armamentarium available, I concur with the recommendations for accelerated approval.
9. Advisory Committee Meeting
On July 14, 2011, the Oncologic Drugs Advisory Committee (ODAC) met in the morning to discuss this application. ODAC voted unanimously in favor of accelerated approval for this application.

10. Pediatrics
This product has Orphan Drug Designation.

11. Other Relevant Regulatory Issues
The Division of Scientific Investigation deemed the data usable for review purposes. Financial Disclosure information was reported and the information did not suggest any significant financial conflict of interest on the part of the investigators. The facilities inspections were acceptable.

12. Labeling
All disciplines made recommendations for labeling which were incorporated.

13. Decision/Action/Risk Benefit Assessment

- Recommended regulatory action
  Accelerated Approval

- Risk Benefit Assessment
The risk benefit assessment favors approval of brentuximab vedotin for the treatment of patients with Hodgkin Lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not candidates for an autologous stem cell transplant. The overall response rate was impressive. The responses were durable for those who achieved a complete remission. The responses were not very durable for those whose disease achieved a partial response. The safety data base was limited as only 102 patients were enrolled in SG035-0003. The major adverse events were neuropathy, neutropenia, and infusion reactions. Due to the limited safety database, the approval recommendation is for accelerated approval with commitments from the sponsor to provide additional safety data.

- Recommendation for Post marketing Risk Management Activities
  Routine Surveillance
• Recommendation for other Post marketing Study Requirements/Commitments (See approval letter for final wording)

Post-Marketing Requirements

For conversion to regular approval

A randomized phase 3, double-blind, placebo-controlled trial of SGN-35 (brentuximab vedotin) in combination with CH-P versus CHOP as frontline therapy in patients with CD30-positive mature T- and NK-cell lymphomas including systemic ALCL (sALCL). Enrollment of approximately 300 patients is planned with a primary endpoint of progression free survival as determined by an independent blinded review facility. Overall survival is a key secondary endpoint.

Final Protocol Submission Date: 3/31/2013
Study/Trial Completion Date: 3/31/2019
Final Report Submission Date: 9/30/2019

A randomized phase 3 trial of SGN-35 (brentuximab vedotin) in combination with AVD versus ABVD as frontline therapy in patients with advanced Hodgkin Lymphoma. Enrollment of approximately 880 patients is planned with a primary endpoint of progression free survival determined by an independent blinded review facility. Overall survival is a key secondary endpoint.

Final Protocol Submission Date: 09/30/2012
Study/Trial Completion Date: 12/31/2018
Final Report Submission Date: 06/30/2019

For characterization of the reversibility/resolution of drug-induced peripheral neuropathy.

Characterize the severity, duration and reversibility of treatment emergent neuropathy in a prospective trial.

The ongoing placebo-controlled AETHERA trial safety results may be utilized to address this PMR.

Phase 3 Trial Completion Date: 12/31/2013
Phase 3 Trial Final Report Submission Date: 6/30/2014

Post-marketing Study Commitments

Perform additional experimental work to understand the impact of soluble CD30 in serum samples on the determination of anti-drug antibodies.

Final Report Submission Date: 09/30/2012

Provide summary data for validating all in-process product intermediate maximum hold times for the cAC10 manufacturing process at scale in a CBE0.
Perform the bacteriostasis/fungistasis testing for the bioburden test of the bulk drug substance using three batches of BDS samples stored under routine sample storage conditions at 2-8°C.

Commit to reassess brentuximab vedotin drug substance and drug product specifications based on the combination of Intermediate lots used to manufacture SGN-35 BDS and DP when the total number of BDS and DP lots include ≥25 lots cAC10 and ≥10 lots of SGD-1006 as input intermediates and, as part of your annual Product Quality Review for brentuximab vedotin.

Harmonize all CMC information contained in your application with that contained in DMF

Reevaluate the Limit of Detection (LOD) of methylene blue using standard curve with different concentrations of dye that include concentrations below the LOD. Results of the LOD determination will be appended to the method validation report and communicated to the FDA before the end of December 2011.

The CDRH guidance referenced for biological indicator (BI) incubation time has been superseded by the CDRH Guidance on BI Premarket Notification 510(k) Submissions. The guidance refers to BIs used to monitor sterilization processes in health care facilities. BIs intended for use in a manufacturing setting are excluded. The Test BIs used for validation studies should be to confirm that all BIs are negative. This change should be made to the validation protocols at and reported in the next annual report.